✦ LIBER ✦

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

✍ Scribed by Armando Santoro; Lorenza Rimassa; Alberto F. Sobrero; Giovanni Citterio; Francesco Sclafani; Carlo Carnaghi; Anna Pessino; Francesco Caprioni; Valeria Andretta; Maria Chiara Tronconi; Giovanna Finocchiaro; Gloria Rossoni; Angela Zanoni; Chiara Miggiano; Gian-Paolo Rizzardi; Catia Traversari; Federico Caligaris-Cappio; Antonio Lambiase; Claudio Bordignon

Book ID: 116430477
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 206 KB
Volume: 46
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2010.07.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6062 NGR-hTNF, a vascular targeting agen

6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study

✍ Rimassa, L.; Santoro, A.; Sobrero, A.F.; Sclafani, F.; Gregorc, V.; Andretta, V. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

6066 Phase II study of two doses of NGR-

6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens

✍ Sobrero, A.F.; Pessino, A.; Andretta, V.; Bennicelli, E.; Fornarini, G.; Caprion 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

6617 Phase II study of NGR-hTNF, a selec

6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)

✍ Santoro, A.; Citterio, G.; Pressiani, T.; Gregorc, V.; Rimassa, L.; De Braud, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Phase Ib study of NGR–hTNF, a selective

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

✍ Gregorc, V; Santoro, A; Bennicelli, E; Punt, C J A; Citterio, G; Timmer-Bonte, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 216 KB

1228 Phase I study of NGR-hTNF, a vascul

1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

✍ G. Citterio; F.G. De Braud; V. Gregorc; T.M. De Pas; C. Noberasco; S. Boselli; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Optimisation of irinotecan dose in the t

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

✍ Van Cutsem, E; Dirix, L; Van Laethem, J-L; Van Belle, S; Borner, M; Gonzalez Bar 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 108 KB